Showing 5871-5880 of 8887 results for "".
- SCUBE3 May Stimulate Hair Growthhttps://practicaldermatology.com/news/scube3-may-stimulate-hair-growth/2461254/University of California, Irvine-led researchers have discovered that a signaling molecule called SCUBE3 potently stimulates hair growth and may offer a therapeutic treatment for androgenetic alopecia, according to a study published in
- Study: Colorescience’s All Calm Regimen Reduces Redness, Inflammationhttps://practicaldermatology.com/news/study-coloresciences-all-calm-regimen-reduces-redness-inflammation/2461253/Colorescience’s All Calm Regimen calms inflammation and reduces redness, according to a new study in the Journal of Cosmetic Dermatology. The 12-week study consisted of two subject groups. Group A subjec
- Study: Females Itch Less than Maleshttps://practicaldermatology.com/news/study-females-itch-less-than-males/2461252/Females have a significantly lower incidence of severe psoriasis, however, the underlying reason for the sex differences has remained unclear. Now, a team of researchers has found that the female hormone estradiol suppresses psoriasis, and the protective role of the hormone ha
- Phase 3 PSOARING 3 Long-Term Extension Study Data Positive for Tapinarof Creamhttps://practicaldermatology.com/news/phase-3-psoaring-3-long-term-extension-study-data-positive-for-tapinarof-cream/2461251/New data from the one-year safety and efficacy final analyses of the Phase 3 PSOARING 3 long-term, open-label extension (“LTE”) study of Dermavant Sciences' VTAMA (tapinarof) cream, 1% for the treatment of plaque psoriasis in adults was published in the
- FDA Clears Soligenix's Synthetic Hypericin for Phase 2 Clinical Trial in Psoriasishttps://practicaldermatology.com/news/fda-clears-soligenixs-synthetic-hypericin-for-phase-2-clinical-trial-in-psoriasis/2461250/The U.S. Food and Drug Administration (FDA) has cleared Soligenix’s Investigational New Drug (IND) application for a Phase 2a clinical trial of topically-applied SGX302 (synthetic hypericin). Patient enrollment is slated to begin in the fourth quarter of 2022. "Duri
- Researchers ID Sensor Underlying Mechanical Itchhttps://practicaldermatology.com/news/researchers-id-sensor-underlying-mechanical-itch/2461248/Scientists at Scripps Research have identified a protein in sensory nerves that works as a key detector of the “mechanical” itch stimulus of crawling insects, wool fibers, or other irritating objects that touch the skin. The discovery, published June 22, 2022, in Nature
- TruSkin SPF 30 Mineral Sunscreen with Vitamin C Launcheshttps://practicaldermatology.com/news/truskin-spf-30-mineral-sunscreen-with-vitamin-c-launches/2461245/New from TruSkin, TruSkin SPF 30 Mineral Sunscreen with Vitamin C features non-nano zinc oxide in a lightweight, non-greasy formula with asheer finish intended to blend into a
- Dermatologists Rule for Cosmetic Procedures and Skin Care Decisionshttps://practicaldermatology.com/news/dermatologists-rule-for-cosmetic-procedures-and-skin-care-decisions/2461241/Dermatologists rank as the number one influencer among 16 factors that impact consumers’ decisions to have a cosmetic procedure, according to the 2021
- ProofPilot Wants You to Submit Research Ideas on Issues Concerning BIPOC Communitieshttps://practicaldermatology.com/news/proofpilot-wants-you-to-submit-research-ideas-on-issues-concerning-bipoc-communities/2461237/ProofPilot, a Software as a Service (SaaS) clinical trial research platform, is rolling out its first ever Open Invitation for Research, in partnership with the nonprofit organization
- Vial Dermatology CRO adds Dr. Jonathan Zung to Scientific Advisory Boardhttps://practicaldermatology.com/news/vial-dermatology-cro-adds-dr-jonathan-zung-to-scientific-advisory-boar/2461236/The Vial Dermatology CRO welcomed Jonathan Zung, PhD, as the newest addition to the Vial Scientific Advisory Board. Dr. Zung will support the Vial CRO team and their sponsors to further advance the field of dermatology clinical researc